Editorially Independent Content, Supported with Advertising from: Allergan XEN, Glaukos iStent, New World Medical, Nova Eye, & Sight Sciences.
Jacob Brubaker, MD, Arsham Sheybani, MD, Iqbal Ike K. Ahmed, MD, FRCSC
Show Description +
Iqbal Ike K. Ahmed, MD, FRCSC, discusses the management of patients who received a CyPass Micro-Stent (Alcon; no longer on the market) with Jacob Brubaker, MD, and Arsham Sheybani, MD. Dr. Ahmed shares a case of a 70-year-old man who underwent cataract surgery combined with implantation of a CyPass Micro-Stent 3 years ago. Although IOP was 11 mm Hg without medication at a recent visit, the implant appeared to be in contact with the corneal endothelium. Learn more about risk stratification and strategies for management in patients who have this glaucoma device.
Posted: 3/22/2019
Jacob Brubaker, MD, Arsham Sheybani, MD, Iqbal Ike K. Ahmed, MD, FRCSC
Iqbal Ike K. Ahmed, MD, FRCSC, discusses the management of patients who received a CyPass Micro-Stent (Alcon; no longer on the market) with Jacob Brubaker, MD, and Arsham Sheybani, MD. Dr. Ahmed shares a case of a 70-year-old man who underwent cataract surgery combined with implantation of a CyPass Micro-Stent 3 years ago. Although IOP was 11 mm Hg without medication at a recent visit, the implant appeared to be in contact with the corneal endothelium. Learn more about risk stratification and strategies for management in patients who have this glaucoma device.
Posted: 3/22/2019
Please log in to leave a comment.